Monoclonal Antibodies (Mabs) Market Poised for Disruptive Growth by...

Monoclonal Antibodies (Mabs) Market Poised for Disruptive Growth by 2032

Сообщение 2025-05-13 09:52:49

The global monoclonal antibodies market was valued at USD 185.07 billion in 2021 and is expected to grow at a compound annual growth rate (CAGR) of 11.5% during the forecast period. The market's growth is driven by increasing prevalence of chronic diseases such as cancer, autoimmune disorders, and infectious diseases, along with rising adoption of targeted therapies.

Key Market Drivers

Rising demand for personalized medicine and biologics
Expanding application in oncology, immunology, and infectious diseases
Technological advancements in antibody engineering and production
Growing approvals and launches of new monoclonal antibody therapies

Leading Market Players

Abbott Laboratories
Amgen Inc.
AstraZeneca plc
Bayer AG
Biogen Inc.
Bristol Myers Squibb
Daiichi Sankyo Company Limited
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
GlaxoSmithKline plc
Johnson & Johnson Services, Inc.
Merck & Co., Inc.
Merck KGaA
Novo Nordisk A/S
Novartis
Pfizer Inc.
Sanofi S.A.
Thermo Fisher Scientific, Inc.
Viatris Inc.

Market Outlook
As biologics continue to gain prominence in global therapeutics, the monoclonal antibodies market is expected to witness sustained growth. Increasing investments in R&D, coupled with a strong pipeline of monoclonal antibody candidates, will further enhance the market's trajectory through the coming years.

Eyewear Market

Precision Farming Market

Restaurant Point-Of-Sale (Pos) Terminals Market

Earphones And Headphones Market

Engineering Services Outsourcing Market

Multiple Sclerosis Market

Medical Tourism Market

Next Generation Sequencing (Ngs) Market

Sports Medicine Market

Ultrasound Transducer Market

Peripheral Vascular Device Market

Transcatheter Aortic Valve Replacement (TAVR) Market